250 related articles for article (PubMed ID: 29857476)
1. Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.
Rabien A; Ratert N; Högner A; Erbersdobler A; Jung K; Ecke TH; Kilic E
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29857476
[TBL] [Abstract][Full Text] [Related]
2. Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.
Prodromaki E; Korpetinou A; Giannopoulou E; Vlotinou E; Chatziathanasiadou Μ; Papachristou NI; Scopa CD; Papadaki H; Kalofonos HP; Papachristou DJ
Cell Oncol (Dordr); 2015 Aug; 38(4):307-17. PubMed ID: 26227789
[TBL] [Abstract][Full Text] [Related]
3. Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder.
Yang FQ; Huang JH; Liu M; Yang FP; Li W; Wang GC; Che JP; Zheng JH
Int J Clin Exp Pathol; 2014; 7(1):340-7. PubMed ID: 24427355
[TBL] [Abstract][Full Text] [Related]
4. EIF2C, Dicer, and Drosha are up-regulated along tumor progression and associated with poor prognosis in bladder carcinoma.
Zhang Z; Zhang G; Kong C; Bi J; Gong D; Yu X; Shi D; Zhan B; Ye P
Tumour Biol; 2015 Jul; 36(7):5071-9. PubMed ID: 25656609
[TBL] [Abstract][Full Text] [Related]
5. Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder.
Han Y; Liu Y; Gui Y; Cai Z
J Surg Oncol; 2013 Feb; 107(2):201-5. PubMed ID: 22766726
[TBL] [Abstract][Full Text] [Related]
6. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder.
Yu HJ; Chang YH; Pan CC
Histopathology; 2013 Apr; 62(5):788-98. PubMed ID: 23425286
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of Ki67 and p63 expressions in bladder cancer patients who underwent radical cystectomy.
Wang L; Zhou M; Feng C; Gao P; Ding G; Zhou Z; Jiang H; Wu Z; Ding Q
Int Urol Nephrol; 2016 Apr; 48(4):495-501. PubMed ID: 26759323
[TBL] [Abstract][Full Text] [Related]
9. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma].
Guo YS; Dai YP; Li W; Liu LD
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):28-31. PubMed ID: 21575460
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy.
Kolla SB; Seth A; Singh MK; Gupta NP; Hemal AK; Dogra PN; Kumar R
Int Urol Nephrol; 2008; 40(2):321-7. PubMed ID: 17899426
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas.
Chang CC; Tai CJ; Su TC; Shen KH; Lin SH; Yeh CM; Yeh KT; Lin YM; Jiang MC
Ann Diagn Pathol; 2012 Oct; 16(5):362-8. PubMed ID: 22476051
[TBL] [Abstract][Full Text] [Related]
13. A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression.
Kawaguchi M; Hara N; Bilim V; Koike H; Suzuki M; Kim TS; Gao N; Dong Y; Zhang S; Fujinawa Y; Yamamoto O; Ito H; Tomita Y; Naruse Y; Sakamaki A; Ishii Y; Tsuneyama K; Inoue M; Itoh J; Yasuda M; Sakata N; Jung CG; Kanazawa S; Akatsu H; Minato H; Nojima T; Asai K; Miura Y
BMC Cancer; 2016 Oct; 16(1):805. PubMed ID: 27756245
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
[TBL] [Abstract][Full Text] [Related]
15. Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder.
Hodgson A; Xu B; Satkunasivam R; Downes MR
J Clin Pathol; 2018 Feb; 71(2):154-160. PubMed ID: 28768702
[TBL] [Abstract][Full Text] [Related]
16. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
Korkolopoulou P; Konstantinidou AE; Thomas-Tsagli E; Christodoulou P; Kapralos P; Davaris P
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):285-92. PubMed ID: 11127920
[TBL] [Abstract][Full Text] [Related]
17. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
18. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
19. Expression profile of microrna-145 in urothelial bladder cancer.
Dip N; Reis ST; Srougi M; Dall'Oglio MF; Leite KR
Int Braz J Urol; 2013; 39(1):95-101; discussion 102. PubMed ID: 23489501
[TBL] [Abstract][Full Text] [Related]
20. TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis.
Levidou G; Thymara I; Saetta AA; Papanastasiou P; Pavlopoulos P; Sakellariou S; Fragkou P; Patsouris E; Korkolopoulou P
Pathology; 2013 Feb; 45(2):138-44. PubMed ID: 23277172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
